Neurocrine Biosciences · 9 hours ago
Business Development Intern
San Diego, CA
Internship
Onsite
InternNeurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to discovering and developing life-changing treatments. They are offering an internship opportunity to gain business development experience, focusing on competitive intelligence processes and corporate strategy activities.
BiotechnologyHealth CarePharmaceutical
Responsibilities
Monitoring industry trends, companies, technologies, and therapeutic areas of relevance to Neurocrine
Supporting a range of activities, including product and technology assessment
Interacting with multiple functional areas within the company such as research, clinical development, and finance
Completing a special project and presenting the recommendations to senior management upon completion
Qualification
Required
Third-year undergraduate student with major in the life sciences (e.g., Neuroscience, Biology, Molecular and Cell Biology)
Interest in learning about the biopharmaceutical industry including technologies, product development, and regulatory approval processes
Good verbal and written communication skills
Ability to think creatively and be a team player
Offer flexibility with a willingness to work on multiple projects simultaneously
Bring to the Company a skill set complementary to its technologies and therapeutics in development
Interest in attending various program events, including social gatherings, career development workshops, and more
Ability to commit to a 10-week, full-time summer program (in-person in San Diego, CA)
Preferred
Market research experience or experience in the pharmaceutical or biotechnology industry would be an asset but is not required
Company
Neurocrine Biosciences
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Founded in 1992
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$260MKey Investors
Venrock
2015-02-19Post Ipo Equity· $250M
2009-12-17Post Ipo Equity· $10M
1996-05-31IPO
Leadership Team
Matt Abernethy
Chief Financial Officer
D
Dimitri Grigoriadis
VP, Research
Recent News
2026-01-06
Company data provided by crunchbase